PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer

Metastatic Gastric Cancer Clinical Trial

Official title:

Phase II Clinical Study of PD-1 Antibody Camrelizumab Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Localized Metastatic Gastric Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04510064
• Other study ID #: FDZL-PFG
• Status: Recruiting
• Phase: Phase 2
• Start date: August 2020
• Est. completion date: August 2022

Study information

• Verified date: August 2020
• Source: Fudan University
• Contact: weijian guo, professor
• Phone: +86-21-64175590
• Email: guoweijian[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the efficacy and safety of domestic programmed death 1（ PD-1） antibody (Camrelizumab for injection) combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (modified FLOT, mFLOT) regimen in the treatment of patients with unresectable locally advanced or limited metastatic gastric cancer. The primary efficacy endpoint is R0 resection rate.

Description:

This is an open, single center, prospective phase II clinical study to evaluate the efficacy and safety of domestic PD1 antibody (Camrelizumab for injection) combined with mFLOT regimen in the treatment of unresectable locally advanced or limited metastatic gastric cancer. This study will be carried out in our center, about 40 patients will be enrolled.

Patients with unresectable locally advanced or limited metastatic gastric cancer who had not received any prior antitumor therapies were treated with domestic PD1 antibody (Caerelizumab for injection) commbined with mFLOT regimen, and human epidermal-growth-factor receptor 2 (HER-2) positive patients were treated with Herceptin. The efficacy of therapy was evaluated every 3 treatment cycles. After 6 cycles, surgical experts evaluated the resectability of the tumor, and the patients who were confirmed to be resectable received surgery within 3-6 weeks after immunochemotherapy. The patients with good postoperative recovery continued to receive the same immunochemotherapy in 3-6 weeks, and totally at most 12 cycles. Patients who were evaluated as progressive disease (PD) at any time withdrawn from the study as conversion failure.Patients who did not PD at 6 cycles of treatment but did not reach the criteria for R0 resection, continued to receive another 3 cycles of the prior chemotherapy. If resectable then, surgical treatment was performed, if still unresectable, the immunochemotherapy for transformation was evaluated as unsuccessful. The patients were treated according to the principle of palliative treatment until the disease progressed or intolerable toxicity. The efficacy and safety will be continuously monitored and evaluated throughout the study period (including a 30 day follow-up period). 40 cases were expected to be enrolled: 3-4 cases per month, completed in 1 year and finished in 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: August 2022
• Est. primary completion date: August 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent obtained.

• Age = 18 years at time of study entry, no gender limit.

• Participants must have histologically or cytologically confirmed adenocarcinoma of the stomach (including adenocarcinoma of the gastroesophageal junction).

• At least one measurable site of disease as defined by RECIST criteria with spiral CT scan or MRI.

• CT or MRI showed unresectable locally advanced gastric cancer (imaging stage T4b and / or second station lymph node > 3cm or fusion mass) or limited metastatic gastric cancer with any of the following single site metastasis:

1. Retro-peritoneal lymph node metastasis (RPLM) (e.g. para-aortic, intra-aorto-caval, para-pancreatic or mesenteric lymph nodes).

2. Single or bilateral Krukenberg tumors.

3. No more than 5 liver metastases, and the maximum diameter of the lesions was less than 5 cm.

4. Adrenal metastasis.

5. Localized potentially operable peritoneal carcinomatosis: stage P1 according to classification of the"Japanese Research Society for Gastric Cancer (JRSCGC)".

• No clinically visible peritoneal metastasis (such as CT imaging confirmation or ascites).

• No prior anti-tumor therapy.

• Performance status (PS) < 2 (ECOG scale).

• Life expectancy of at least 12 weeks.

• Adequate blood count, liver-enzymes, and renal function: hemoglobin=90g/dL,absolute neutrophil count = 1.5×109/L, platelets =100 x109/L; Total bilirubin < 1.5x upper normal limit (UNL), Aspartate Aminotransferase (SGOT), Alanine aminotransferase (SGPT) <2.5 x ULN, if liver metastasis existed, SGOT,SGPT<2.5xULN. International normalized ratio (INR) =2.5 x ULN, Serum Creatinine = 1 x institutional ULN or creatinine clearance (CrCl) >50ml/min (if using the Cockcroft-Gault formula ).

• Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.

• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, adherence to contraceptive measures, scheduled visits and examinations including follow up.

Exclusion Criteria:

• A history of other malignancies within 3 years prior to enrollment, except for cervical carcinoma in situ or skin basal cell carcinoma that had been cured.

• Accompanied with brain or meningeal metastasis.

• Malignant pleural and peritoneal effusion.

• Accompanied by gastrointestinal obstruction, gastrointestinal bleeding (fecal occult blood +++ )or perforation.

• Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137,or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

• Has an active or history of autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or with high risk (such as receiving immunosuppressive therapy after organ transplantation), but in the past two years with vitiligo, psoriasis, alopecia or Graves' disease without systemic treatment, hypothyroidism with thyroid hormone replacement therapy only and type I diabetes only need insulin replacement therapy can be enrolled.

• Suffering from interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease and radiation pneumonia.

• Participate in other clinical studies of drugs (subject to the use of trial drugs) within 4 weeks before the first administration, unless participating in observational (non intervention) clinical studies.

• Used immunosuppressive drugs within 4 weeks before the first dose of study treatment, excluding nasal, inhalation or other local glucocorticoids or physiological doses of systemic glucocorticoids (i.e. no more than 10mg prednisone or equivalent dose of other glucocorticoids, or short-term (no more than 7 days) use of glucocorticoids to prevent or treat non autoimmune allergic diseases.

• Planned to receive live attenuated vaccine within 4 weeks before the first dose of study treatment or during the study period. Note: inactivated virus vaccine for seasonal influenza is allowed within 4 weeks before the first administration, however, live attenuated influenza vaccine is not allowed.

• Major surgery (craniotomy, thoracotomy or laparotomy) was performed within 4 weeks before the first dose of study treatment, or major surgery (not in this study) was expected to be performed during the study treatment.

• A history of HIV infection (i.e. HIV antibody positive), or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or stem cell transplantation.

• Patients with active chronic hepatitis B or active hepatitis C, hepatitis B virus carriers. Stable hepatitis B after drug treatment (DNA titer not higher than 200iu/ml or copy number < 1000copies / ml) and cured patients with hepatitis C (HCV RNA test negative) can be included in the group.

• Active tuberculosis.

• Severe infection within 4 weeks before the first administration, or active infection within the first 2 weeks and requiring oral or intravenous antibiotic treatment.

• Symptomatic congestive heart failure (NYHA grade II-IV) or symptomatic or poorly controlled arrhythmias;

• Uncontrolled arterial hypertension (systolic blood pressure=160mmhg or diastolic blood pressure=100mmhg) even after standard treatment.

• Any arterial thromboembolism events, including myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before the treatment.

• A history of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism within 3 months before enrollment (implantable venous infusion port or catheter-derived thrombosis, or superficial venous thrombosis is not considered as "severe" thromboembolism)

• Have a clear history of neurological or mental disorders in the past, such as epilepsy, dementia, poor compliance, or patients with peripheral nervous system disorders.

• Alcohol addicts or have a history of drug use or drug abuse in the past 1 yea.

• Pregnant or lactating women, fertile women without adequate contraceptive measures

• Other acute or chronic diseases, mental disorders, or laboratory test value abnormalities that may result in increased risk associated with study participation or drug administration, or interference with the interpretation of the study results, and the patient, in the judgment of the investigator, is not eligible to participate in the study.

Related Conditions & MeSH terms

• Locally Advanced Gastric Adenocarcinoma
• Metastatic Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Camrelizumab plus mFLOT regimen
Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks, and HER-2 positive patients were added with Herceptin therapy. Camrelizumab 200mg on day 1, albumin bound paclitaxol 125mg/m² on day 1,oxaliplatin 85 mg/m² on day 1, leucovorin 200 mg/m² on day 1, and 5-FU 2600 mg/m² as 24-h infusion on day 1.Herceptin 6mg/Kg at the first time, followed by 4mg/Kg if needed.

Procedure:
• R0 surgery
The efficacy of therapy was evaluated every 3 treatment cycles. If the tumor can be R0 resected after 6-9 cycles, then proceeded to surgery. After the operation, patients continued to receive the prior immunotherapy totally to 12 cycles or to the disease progressed or intolerable toxicity.

Locations

Country	Name	City	State
China	Fudan University, Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	margin-free-(R0) resection rate	R0 resection was defined as no tumor identified on microscopic examination of proximal, distal,or circumferential margins.	6-9 weeks after immunochemotherapy
Secondary	pathological complete response (pCR)		6-9 weeks after immunochemotherapy and R0 surgery
Secondary	overall response rate (ORR)		up to 24 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0		up to 24 months
Secondary	sugery complications	sugery complications	up to 2 months after the period of surgery
Secondary	progression free survival (PFS)	randomisation to disease progression, relapse, or death; surgical morbidity and mortality	up to 24 months
Secondary	overall survival (OS)		up to 24 months